Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study
Saved in:
| Published in: | Cancer Medicine |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867301678914469889 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Cancer Medicine |
| description | |
| discipline_display | Oncology |
| discipline_facet | Oncology |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:61130 |
| institution | FRELIP |
| journal_source_facet | Cancer Medicine |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study Oncology General Oncology |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Oncology General Oncology Oncology General Oncology |
| subject_facet | Oncology General Oncology |
| title | Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study |
| title_auth | Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study |
| title_full | Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study |
| title_fullStr | Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study |
| title_full_unstemmed | Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study |
| title_short | Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study |
| title_sort | acalabrutinib versus venetoclax plus obinutuzumab in treatment‐naive chronic lymphocytic leukemia: a real‐world propensity score‐matched study |
| topic | Oncology General Oncology |
| url | https://onlinelibrary.wiley.com/doi/10.1002/cam4.72022?af=R |